Document:

QuickLinks
 -- Click here to rapidly navigate through this document
  

 
 

Exhibit 10.47    
    

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

 
 

NON-EXCLUSIVE LICENSE AGREEMENT
  By and Between
  IMMUNICON CORPORATION
  and
  STRECK LABORATORIES, INC.    
    

        THIS NON-EXCLUSIVE LICENSE AGREEMENT (hereinafter "Agreement"), dated and effective as of the Effective Date (as hereinafter defined), is by and
between Immunicon Corporation, having an address at 3401 Masons Mill, Suite 100, Huntingdon Valley, Pennsylvania 19006 (hereinafter "Immunicon"), and Streck Laboratories, Inc., having an
address at 7002 South 109th Street, La Vista, NE 68128 (hereinafter "Streck"), on behalf of each of them and their Affiliates (as hereinafter defined). 

WITNESSETH:  

        WHEREAS, Immunicon is engaged in the development and commercialization of products in the biomedical field including cell-based diagnostic and related
products, and Streck is engaged in manufacturing and commercializing technology for the preservation of cells in samples of blood and other fluids for various uses, including uses in the biomedical
field; and 

        WHEREAS,
each party sees a mutual benefit in the use by Immunicon of certain of Streck's technology in the research, development, manufacturing, marketing and sales of IC Tests and IC
Sample Tubes by Immunicon which utilize and/or incorporate Streck's technology; and 

        WHEREAS,
Immunicon and its Affiliates wish to receive from Streck a worldwide, non-exclusive license under applicable patent and other proprietary rights of Streck, and
Streck wishes to grant such a license and to provide Immunicon with associated formulation and manufacturing know-how and other proprietary information, under the terms and conditions of 

-1-

 

this
Agreement, in order to enable Immunicon and its Affiliates (as hereinafter defined) to research and have researched, develop and have developed, manufacture and have manufactured, Licensed
Products (as hereinafter defined) to be used in the research, development, manufacture and sale of IC Tests and IC Sample Tubes; and 

        WHEREAS,
in order to accomplish the foregoing, Streck and Immunicon desire to set forth herein the terms and conditions under which the aforementioned license shall be granted; 

        NOW,
THEREFORE, in consideration of the foregoing premises, the mutual covenants herein contained and other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties hereto agree as follows: 

	1.
	DEFINITIONS.

Certain
terms are used in this Agreement as specifically defined herein. In addition: 

	1.1
	"Affiliate"
means each and every corporation or other business entity controlled by, controlling or under common control with or by a party. For the purposes of this definition, the
word and root "control," in the context of a corporation, means direct or indirect beneficial ownership of at least fifty percent (50%) of the shares entitled to vote for members of the board of
directors of such corporation and, in the context of any other business entity, means the right to receive at least fifty percent (50%) of the income of such business entity.

	1.2
	"Cyto-Chex
Immunicon formulation" means the formulation of Cyto-Chex produced according to Streck Manufacturing Formulation Sheet [**].

	1.3
	"Effective
Date" means July 1, 2002.

	1.4
	"IC
Test" means a diagnostic assay or test product incorporating therein or utilizing the Licensed Products or Streck Technology, including all reagents and other materials associated
therewith for performing the assay or test, in a packaged form intended for commercial sale by Immunicon or an Affiliate of Immunicon to a third party who is not an Affiliate of either party. For the
avoidance of doubt and by way of example and not limitation, IC Test shall not include any product which is used by or in research, product development or demonstration or which is provided without
charge to an Immunicon Affiliate or used by such Affiliate, or which is provided to any third party as free product,

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

-2-

 
	

	marketing
or sales samples or the like or as a product sample for evaluation, or which is provided for use in research or clinical trials or similar studies and
activities.

	1.5
	"IC
Sample Tube" means an individual sample container designed to contain a sample of fluid from a patient, which sample is suspected of containing epithelial cells or circulating
tumor cells, and upon which sample, after placement of the sample in the container, an IC Test is to be performed, and which container utilizes or contains the Licensed Products or Streck Technology.

	1.6
	"Immunicon
IC Sample Tube Formulation" means the formulation of Cyto-Chex for use in IC Sample Tubes produced according to Streck Manufacturing Formulation
[**].

	1.7
	"Streck
Technology" means Streck's patents and patent applications ("Streck Patents") and other proprietary information and know-how, including without limitation all
methods, compositions, materials and all manufacturing formulas, processes, procedures and similar information required to manufacture the Licensed Products and only the Licensed Products. Streck
Technology which is not contained in Streck Patents shall be provided to Immunicon in written or other tangible form by Streck from time to time during the term of this Agreement, in accordance with
the provisions hereof. Streck Technology relevant to this Agreement as of the Effective Date is listed in Appendix A.

	1.8
	"Licensed
Products" means Cyto-Chex Immunicon formulation and Immunicon IC Sample Tube formulation or any product that incorporates or utilizes Streck Technology pursuant
to the license granted by Streck hereunder.

	1.9
	"Net
Sales" means the gross amount of all moneys or other thing(s) of value received from the sale or other transfer of IC Tests or IC Sample Tubes to unaffiliated third parties by
Immunicon or its Affiliates in the ordinary course of business. Net Sales shall not include any transfer of any product which is provided by Immunicon to any third party as free product, marketing or
sales samples or the like or as a product sample for evaluation, or which is provided for use in research or clinical trials or similar studies and activities.

	2.
	TERM
AND TERMINATION.

	2.1
	This
Agreement shall commence on the Effective Date, and shall continue for the life of the last to expire of the relevant Streck Patents, unless one of the termination options
identified in this Article 2 applies.

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

-3-

 
	2.2
	Termination by Mutual Consent. This Agreement shall terminate upon the mutual written agreement of the parties.

	2.3
	Termination for Financial Difficulties. Either party shall have the right to terminate this Agreement upon thirty (30) days
notice to the other party, if such other party becomes involved in financial difficulties as evidenced:

	a)
	by
such other party's commencement of a voluntary case under any applicable bankruptcy code or statute, or by its authorizing, by appropriate proceedings, the commencement of such a
voluntary case; or

	b)
	by
such other party's failing to receive dismissal of any involuntary case under any applicable bankruptcy code or statute within sixty (60) days after initiation of such action
or petition; or

	c)
	by
such other party's seeking relief as a debtor under any applicable law of any jurisdiction relating to the liquidation or reorganization of debtors or to the modification or
alteration of the rights of creditors, or by consenting to or acquiescing in such relief; or

	d)
	by
the entry of an order by a court of competent jurisdiction finding such other party to be bankrupt or insolvent, or ordering or approving its liquidation, reorganization, or any
modification or alteration of the rights of its creditors or assuming custody of, or appointing a receiver or other custodian for, all or a substantial part of its property or assets; or

	e)
	by
such other party making an assignment for the benefit of, or entering into a composition with, its creditors, or appointing or consenting to the appointment of a receiver or other
custodian for all or a substantial part of its property.

	2.4
	Termination for Material Breach. If either party breaches or defaults in the performance or observance of any of the material
provisions of this Agreement, and such breach or default is not cured within sixty (60) days after the giving of notice by the other party specifying such breach or default, the
non-defaulting party shall have the right to terminate this Agreement, effective with ten (10) days further notice to the defaulting party. The failure by a party to exercise its
right to terminate this Agreement pursuant to this Section 2.4 in the event of any occurrence giving rise thereto shall not constitute waiver of its rights in the event of any subsequent
occurrence. 

-4-

 
	2.5
	Following
the expiration of the last to expire of the Streck Patents or if there are no valid and enforceable claims of Streck Patents which cover the Licensed Products, Streck grants
Immunicon and its Affiliates the right to continue to use Streck Technology for the manufacture of the Licensed Products which Streck has provided to Immunicon during the term of this Agreement,
provided that in the event of such use of Streck Technology which is not publicly known or legally available from a third party, Immunicon and its Affiliates shall continue to pay royalty on Net Sales
as provided herein, except that the royalty amounts set forth in Sections 7 (b) and 7 (c) shall be reduced by [**].

	2.6
	Except
as otherwise provided in this Agreement, upon any expiration or termination of this Agreement:

	a)
	All
rights, privileges and licenses granted hereunder shall immediately terminate and revert to Streck, and Immunicon and its Affiliates shall not thereafter make any use whatsoever of
any Streck Technology, and shall not further manufacture or distribute the Licensed Products, except that Immunicon and its Affiliates shall be permitted to sell such IC Tests and IC Sample Tubes as
may be in their existing inventory as of the date of termination, provided royalty is paid on Net Sales thereof to Streck as provided herein;

	b)
	Immunicon
and its Affiliates shall promptly return or provide to Streck, at its principal place of business, upon the request of Streck, all Streck Technology and other confidential
information disclosed by Streck and existing in tangible form regarding Licensed Products, except that Immunicon may keep an archival copy of such confidential information of Immunicon in the legal
department of Immunicon for the sole purpose of verifying its obligations under this Agreement;

	c)
	Immunicon
and its Affiliates shall promptly destroy or transfer to Streck, at Streck's election, all marketing, labeling, or advertising materials relating to the Licensed Products;
and

	d)
	Immunicon
shall pay to Streck, within thirty (30) days following such expiration or termination, all amounts due to Streck pursuant to the terms and conditions of this
Agreement.

	2.7
	The
provisions of Articles 1, 10 and 11 shall survive any expiration or termination of this Agreement, together with any other express right, obligation or duty of the parties which

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

-5-

 
	

	by
its nature would survive.

	3.
	LICENSE
GRANT.

	3.1
	Streck
hereby grants to Immunicon and its Affiliates a worldwide, non-exclusive right and license to practice the Streck Technology for the research, development,
manufacture of, and to sell and have sold, Licensed Products as a component of IC Tests and IC Sample Tubes and only as a component of IC Tests or IC Sample Tubes.

	3.2
	While
this Agreement is in effect, Immunicon and its Affiliates shall, by way of example and not by way of limitation, have and retain the rights to research, develop, make, have
made, market, sell, distribute and use their own or any third party's cell preservation materials or any other technology in connection with the research, development, use, distribution, marketing and
sale of IC Tests and IC Sample Tubes and to conduct any research and development or testing activity with respect to any cell preservation materials intended for use in or in connection with IC Tests
and IC Sample Tubes.

	4.
	TECHNICAL
ASSISTANCE.

	4.1
	In
order to assist Immunicon in the research, development and manufacturing of the Licensed Products and to expedite commercialization thereof by Immunicon under the rights and
license granted herein, within ten (10) business days following Immunicon's payment of the paragraph 5.1a) fee, Streck shall provide to Immunicon in writing its current best standard
operating procedures, including manufacturing formulations and copies of all relevant Material Safety Data Sheets ("MSDS"), which are necessary in the production of the Licensed Products by Immunicon.
All such information provided by Streck, whether or not included within Streck Technology as defined herein, shall be subject to the provisions of Article 11 governing the confidentiality of
information provided under this Agreement and shall be treated accordingly by Immunicon. In addition, Streck shall provide an amount of technical support to Immunicon, in the form of the assistance of
technically-trained personnel in the formulation and use of Streck Technology, sufficient to enable Immunicon and its Affiliates to research, develop and produce the Licensed Products for
commercialization in accordance with the terms and conditions of this Agreement. Such technical support shall be provided at the reasonable advanced request of Immunicon and its Affiliates, up to
eighty (80) hours during the term 

-6-

 
	

	of
this Agreement. Thereafter, in order to continue to assist Immunicon and its Affiliates with the foregoing, Streck shall from time to time furnish Immunicon with Streck
Technology as may be reasonably requested by Immunicon in connection with the research, development, manufacturing and commercialization of Licensed Products at Streck's then current charge for such
assistance, at Immunicon's expense and to the extent Streck reasonably determines is necessary to assist in such efforts.

	5.
	CONSIDERATION.

	5.1
	As
full consideration of the rights and licenses granted to Immunicon hereunder by Streck, Immunicon shall pay the following amounts to Streck:

	a)
	A
one-time, non-refundable license fee of [**] due and payable on the Effective Date.

	b)
	A
royalty of [**].

	c)
	A
royalty of [**].

	d)
	By
way of example in the calculation of royalty due hereunder, if an IC Test is sold by Immunicon as part of Net Sales, and [**].

	5.2
	Payments
of royalty on account of Net Sales by Immunicon and its Affiliates due Streck hereunder shall be accounted for by Immunicon and paid to Streck within thirty (30) days
following the close of each calendar quarter during the term of this Agreement.

	5.3
	Within
thirty (30) days following each calendar quarter, Immunicon shall provide to Streck a written report setting forth the total Net Sales, total IC Test and IC Sample Tube
sales and the royalty due and payable to Streck for such quarter, and Immunicon shall remit to Streck with such report the amount of royalty payments shown thereby to be due. If there are no Net Sales
to report for the calendar quarter, Immunicon shall provide to Streck a statement to that effect. All royalties shall be paid in United States dollars in the United States. In the event that the Net
Sales or any portion of the Net Sales is accounted for or accrued in a foreign currency, the foreign currency amounts for each calendar quarter shall be converted to United States dollars at the
prevailing rate for the last business day of the quarter as quoted by The Wall Street Journal (or, if The Wall Street Journal is not available, then a comparable publication) or such conversion shall
be accomplished by a procedure to be mutually agreed upon by the Parties.

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

-7-

 
	5.4
	Immunicon
shall keep complete and accurate records for the latest three (3) years showing the Net Sales of the IC Tests and IC Sample Tubes. Such records shall be maintained in
sufficient detail to determine the amount of royalties due hereunder to Streck.

	5.5
	Upon
thirty (30) days' written notice and no more often than once per calendar year, Immunicon agrees to permit one independent auditing firm appointed by Streck (except any to
whom Immunicon has a reasonable objection and provided that the auditing firm has signed a confidentiality agreement with Immunicon or has a similar confidentiality undertaking with respect to the
audit of Immunicon) to enter upon the premises of Immunicon during usual business hours of Immunicon in order to (1) examine Immunicon's business records and accounts pertaining to Immunicon's
manufacture, sale, use, or offer for sale of IC Tests and IC Sample Tubes under this Agreement for the previous twelve (12) calendar quarter(s), and (2) to make on Immunicon's premises
and to retain copies of any and all parts of the records and accounts kept by Immunicon pursuant to this paragraph, including invoices which are relevant to any report required to be rendered by
Immunicon. The foregoing copies of Immunicon's records shall be provided to the auditor(s) at no expense to Streck. The auditor(s) shall provide Streck with their independent calculation of the Net
Sales, IC Tests and IC Sample Tube sales and the application of the appropriate royalty rate so that the total amount of royalties due to Streck under this Agreement may be calculated. Any amounts
found to have been owed but not paid shall be paid to Streck promptly with [**] per annum, and any amounts found to be overpaid by Immunicon shall be refunded promptly to
Immunicon. In the event such audit establishes that Immunicon has underpaid its royalty obligations to Streck under this Agreement by [**] or more during any calendar quarter,
Immunicon shall reimburse Streck for the out-of-pocket expense of such audit. Streck shall not make more than one such request annually. All reports and payments more than
twelve (12) calendar quarters old are deemed to be true and correct and not subject to audit under this paragraph or other remedy under this Agreement. All calendar quarters that were included
in an audit concluded under this paragraph shall not be included in any subsequent audit under this paragraph and shall not be subject to the record retention requirements under this paragraph.

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

-8-

 
	6.
	REPRESENTATIONS,
WARRANTIES AND COVENANTS, INDEMNIFICATION.

	6.1
	Immunicon's Representations, Warranties, and Covenants. Immunicon hereby represents, warrants, and covenants the following:

	a)
	Immunicon
is a corporation duly organized, existing and in good standing under the laws of the state of Delaware, with full right, power and authority to enter into and perform this
Agreement and to grant all of the rights, powers, and authorities herein granted.

	b)
	The
execution, delivery and performance of this Agreement do not conflict with, violate, or breach any agreement to which Immunicon is a party, or Immunicon's articles of incorporation
or bylaws.

	c)
	This
Agreement has been duly executed and delivered by Immunicon and is a legal, valid and binding obligation enforceable against Immunicon in accordance with its terms.

	d)
	Immunicon
shall comply with all applicable laws, consent decrees, and regulations of any federal, state, or other governmental authority.

	6.2
	Streck's Representations, Warranties, and Covenants. Streck hereby represents, warrants, and covenants the following:

	a)
	Streck
is a corporation duly organized, existing and in good standing under the laws of the state of Nebraska, with full right, power, and authority to enter into and perform this
Agreement and to grant all of the rights, powers, and authorities herein granted.

	b)
	The
execution, delivery, and performance of this Agreement do not conflict with, violate, or breach any agreement to which Streck is a party, or Streck's articles of incorporation or
bylaws.

	c)
	This
Agreement has been duly executed and delivered by Streck and is a legal, valid, and binding obligation enforceable against Streck in accordance with its terms.

	d)
	Streck
shall comply with all applicable laws, consent decrees, and regulations of any federal, state, or other governmental authority. 

-9-

 

	e)
	To
the best of Streck's knowledge and belief as of the Effective Date of this Agreement, the Streck Patents are valid and enforceable, and to the best of Streck's knowledge and belief,
there are no issued or pending patent or trademarks of a third party that would prevent Immunicon or its Affiliates from manufacturing Licensed Products or otherwise prevent them from the full
enjoyment of the rights and license granted hereunder. Streck shall have no obligation with respect to the abatement of infringement by third parties of any of the patents and/or know-how
licensed pursuant to this Agreement.

	6.3
	Streck
and its Affiliates hereby covenant that they shall neither sue nor otherwise attempt to enforce against Immunicon or its Affiliates any patents or other proprietary rights
which they now hold, or which they may acquire or develop hereafter, to prevent or restrict Immunicon or its Affiliates from the exercise of any rights granted or permitted to them with respect to
Licensed Products under the terms and conditions of this Agreement, for so long as Licensed Products shall remain subject to the terms and conditions of this Agreement.

	6.4
	Each
party has had the full opportunity to have this Agreement reviewed and approved by its own legal counsel and other advisors, is entering into this Agreement having made its own
independent assessment and judgment concerning the business opportunity and legal rights and obligations under this Agreement and the terms and conditions hereof, and has not been induced to enter
into this Agreement in any way or by any promise not expressly set forth herein.

	6.5
	Immunicon
indemnifies and holds harmless Streck from and against any and all claims, suits, losses, damages, costs, fees and expenses, as incurred, arising from the manufacturing of
the Licensed Products provided, however, that this provision shall not apply to negligent actions or omissions by Streck, its servants, agents or employees. Immunicon represents that it has or will
obtain general and/or product liability insurance in an amount of coverage sufficient to satisfy any of the foregoing which may arise under this Agreement and will provide applicable certificates of
insurance to Streck by August 1, 2002.

	6.6
	Streck
shall indemnify, defend, and hold harmless Immunicon from any and all damages, cost, expenses, suits, claims and judgments (including reasonable attorney's fees and 

-10-

 
	

	costs)
arising or alleged to arise from the conduct of Streck or its officers, employees or agents relating to this Agreement and any breach of Streck's warranties
hereunder, except for any claims, liability, damages, loss, cost, or expense to the extent caused by Immunicon's breach of its warranties herein.

	6.7
	Indemnification Procedure. In the event of any claim under this Article 6, the party claiming the right to indemnity (the
"Claimant") shall promptly notify the indemnifying party (the "Indemnitor") of such claim. Thereafter:

	a)
	The
Indemnitor will undertake the defense thereof by representatives of Indemnitor's own choosing reasonably satisfactory to Claimant. Claimant may, at its sole option and expense,
elect to participate in such defense, but the Indemnitor shall assume the direction and control of such defense. The Claimant shall, at its expense, assist in and cooperate with the Indemnitor and its
agents and insurers in the defense of such claims.

	b)
	If
Indemnitor, within a reasonable time after notice of any such claim, fails to defend, Claimant will (upon further notice to the Indemnitor) have the right to undertake the defense,
compromise or settlement of such claim for the account of Indemnitor, subject to the right of Indemnitor to assume the defense of such claim with counsel reasonably satisfactory to Claimant at any
time prior to settlement, compromise or final determination thereof.

	c)
	Anything
in this Article 6 to the contrary notwithstanding, Indemnitor shall not, without Claimant's prior written consent, settle or compromise any claim or consent to entry of
any judgment with respect to any claim for anything other than money damages paid by Indemnitor which would have any adverse effect on Claimant. Indemnitor may, without Claimant's prior written
consent, settle or compromise any claim or consent to entry of any judgment with respect to any claim which requires solely money damages paid by Indemnitor and which includes as an unconditional term
thereof the release of Claimant by the plaintiff from all liability in respect of such claim. 

-11-

 

	7.
	MARKING.

	7.1
	Immunicon
shall place in a conspicuous location, on the package insert or equivalent literature accompanying any product made or sold under any patent licensed under this Agreement, a
patent notice in accordance with 35 U.S.C. §287,which shall include the number of each such patent and, with respect to any patent licensed under this agreement, Immunicon agrees to
respond to any request for disclosure under 35 U.S.C. §287(b)(4)(B) by only notifying Streck of the request for disclosure

	8.
	FORCE
MAJEURE.

	8.1
	Neither
party hereto shall be considered in default in the performance of its obligations hereunder to the extent that the performance thereof is prevented or delayed by strikes,
labor difficulties, war (declared or undeclared), act of God or the public enemy, rebellions, civil strife, riots, interference by civil or military authorities, compliance with governmental laws, or
rules and regulations or any other cause which is beyond the control of such party; provided, however, that the party whose performance is prevented from due performance hereunder by the force majeure
shall use its reasonable efforts to remove the disability and recommence due performance hereunder at the earliest reasonable time.

	8.2
	On
the happening of an event of force majeure, the party forced by the event of force majeure to suspend performance (the "Suspending Party") shall promptly advise the other party
(the "Recipient Party") of the event of force majeure, the cause thereof and, to the extent reasonably possible its best estimate of the duration of the suspension (the "Failure Period"). The notice
described in this paragraph shall hereinafter be referred to as the "Suspension Notice."

	8.3
	If
any Failure Period continues for a period in excess of twelve (12) months, or if the Suspension Notice states that the Failure Period will continue for greater than twelve
(12) months, the Recipient Party may at its option terminate this Agreement, only with respect to the Licensed Products subject to such force majeure, by thirty (30) days written notice.
If not terminated, however, this Agreement shall remain in full force and effect until this Agreement is terminated by its terms. 

-12-

 
	9.
	ASSIGNMENT.

	9.1
	Except
as otherwise expressly provided herein, this Agreement may not be assigned by either party hereto, whether by operation of law or otherwise, without the prior written consent
of the other party hereto, and any such attempted assignment shall be void and unenforceable; provided, however, that either party may assign its rights and obligations hereunder without the consent
of the other party to an Affiliate of such party, or to a successor in interest to substantially all of the stock, equity or assets of such party to which this Agreement relates.

	10.
	NOTICES.

	10.1
	All
notices which are required or permitted to be given pursuant to the terms of this Agreement shall be in writing and shall be deemed effective: (i) upon receipt if given in
writing and delivered personally; or (ii) five (5) business days after it shall have been deposited in the United States mails, registered or certified mail, postage prepaid; or
(iii) one (1) day after it shall have been delivered to an overnight courier service, such as Federal Express, all charges prepaid, addressed as follows: 

	 	If to Streck, to:	Streck Laboratories, Inc.

P.O. Box 45625

Omaha, NE 68145-0625

Phone: 402.333.1982

Fax: 402.333.5994

Attention: Connie Ryan, President
	

 	

If to Immunicon, to:	

Immunicon Corporation

3401 Mason Mill, Suite 100

Huntingdon Valley, PA 19006

Phone: 215.830.0777

Fax: 215.830.0751

Attention: Edward L. Erickson

Chairman, President and Chief Executive Officer

        Any of the addresses or addressees set forth in this Article may be changed from time to time by written notice from the party requesting the change. 

-13-

 
	11.
	CONFIDENTIALITY
OF INFORMATION.

	11.1
	The
parties may wish, from time to time, in connection with this Agreement, to disclose certain of their confidential information to each other. In order to be subject to
confidential treatment hereunder, such confidential information, if in writing or other tangible form, shall be identified as confidential by the disclosing party in writing at the time of disclosure,
or if disclosed orally or visually, shall be summarized in writing and confirmed in writing as confidential within thirty (30) days following such disclosure, which summary and confirmation
shall be provided to the party receiving any such confidential information (the "Receiving Party"). While this Agreement is in effect and for five (5) years thereafter, the Receiving Party
shall not itself use for any purpose other than for which it was disclosed, and shall prevent the disclosure to third parties of, any and all of such confidential information, provided that the
Receiving Party's obligation hereunder shall not apply to information that:

	a)
	is
already in the Receiving Party's possession at the time of disclosure thereof, as evidenced by its written records;

	b)
	is
or subsequently becomes part of the public domain through no fault or action of the Receiving Party;

	c)
	is
subsequently received by the Receiving Party from a third party having no obligation of confidentiality to the party disclosing the information; or

	d)
	is
disclosed to third parties as required by law or governmental regulation.

	11.2
	Paragraph 11.1
notwithstanding, information disclosed by one party to another shall still be deemed confidential information of the party disclosing such information subject
to the protection of this Article 11 if such disclosed information is:

	a)
	a
specific embodiment that is only generally described by information in the public domain or the Receiving Party's possession; or

	b)
	a
combination that can be pieced together and reconstructed from multiple sources, none of which shows the whole combination of materials, its principle of operation, and method of
use. 

-14-

 

	12.
	MISCELLANEOUS
PROVISIONS.

	12.1
	Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without giving
regard to its choice of law or conflict of laws provisions.

	12.2
	Publicity. Neither party shall issue any press release or other publicity materials, or make any presentation with respect to the
existence of this Agreement or the terms and conditions hereof without the prior written consent of the other party, which consent shall not be unreasonably withheld. This restriction shall not apply
to disclosures required by law or regulation, including as may be required in connection with any filings made with the US Securities and Exchange Commission or by the disclosure policies of a major
Stock Exchange.

	12.3
	Modification and Amendment. No supplement, modification or amendment of this Agreement, including the Appendices hereof, shall be
binding unless in writing and executed by the parties.

	12.4
	Severability. To the extent that any provision of this Agreement is found by a court of competent jurisdiction to violate any
applicable law or regulation in any jurisdiction, or does so in the opinion of counsel mutually acceptable to both parties, such provision shall be deemed modified only in that jurisdiction and only
to the extent necessary to comply with such law or regulation. In such circumstances, the parties agree to negotiate in good faith amendments to this Agreement designed to restore to the parties the
economic benefits they held under this Agreement prior to the modification.

	12.5
	Counterparts and Headings. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument. All headings and captions are inserted for convenience of reference only and shall not affect the meaning or interpretation of any
provision hereof.

	12.6
	Relationship of the Parties. The status of Immunicon and Streck hereunder is solely that of independent contractors. This Agreement
shall not create an agency, partnership, joint venture, or employer/employee relationship between the parties, and nothing hereunder 

-15-

 
	

	shall
be deemed to authorize either party to act for, represent or bind the other except as expressly provided in this Agreement.

	12.7
	Waiver. No waiver of any right under this Agreement shall be deemed effective unless contained in writing and signed by the party
charged with such waiver, and no waiver of any right shall be deemed to be a waiver of any future right or any other right arising under this Agreement. All rights, remedies, undertakings, obligations
and agreements contained in this Agreement shall be cumulative and none of them shall be a limitation of any other remedy, right, undertaking, obligation or agreement.

	12.8
	Patents and Trademarks. No right or license is granted by either party hereunder, except as expressly stated herein, to use or
practice any patent rights of the other party, or to use the name, trademarks or tradenames of the other party. Nothing in this Agreement shall be construed as conferring any right on either party to
use or exploit any trade secret or other proprietary right of the other party, except as expressly set forth herein or as may be otherwise separately agreed in writing by the parties.

	12.9
	Dispute
Resolution. In the event of any dispute between the parties concerning this Agreement, the parties shall first attempt a resolution thereof by referring the dispute to senior
management representatives of each party who shall discuss the matter between them and attempt to reach a reasonable compromise or other disposition of the dispute. In the event such a compromise or
disposition cannot be achieved, the dispute shall be referred to Arbitration. Arbitration shall be conducted by the American Arbitration Association pursuant to its Commercial Arbitration Rules. If
the dispute is brought by Streck, the arbitration proceeding shall be conducted in Philadelphia, Pennsylvania, and if brought by Immunicon, the arbitration proceeding shall be conducted in Omaha,
Nebraska. The award rendered by the arbitrator(s) shall be final and binding upon both parties; judgment upon such decision or award may be entered in any court of competent jurisdiction. Application
may be made to any such court for confirmation of such decision or award, for an order of enforcement and for any other legal or equitable remedies that may be necessary to effectuate such decision or
award. The arbitrator(s) shall have the power to grant injunctive relief enjoining a party from performing any act prohibited, or compelling a party to perform any act required, by the terms of this 

-16-

 
	

	Agreement.
The expenses of such arbitration shall be allocated between the parties as the arbitrators(s) shall decide.

	12.10
	Entire Agreement. This Agreement constitutes the entire agreement between the parties hereto relating to the subject matter hereof
and supersedes all prior or contemporaneous negotiations, representations, agreements and understandings of the parties relating thereto, whether written or oral. Any Appendices referred to in this
Agreement are incorporated by reference and made a part of this Agreement. The terms of any purchase order, equivalent document or acknowledgment prepared in connection with this Agreement shall be
binding on the parties only to the extent not inconsistent herewith. 

        IN
WITNESS WHEREOF, the parties hereto have set their hands through their authorized representatives, whereby they evidence their intention to be legally bound. 

	Streck Laboratories, Inc.	 	Immunicon Corporation
	By:	 	/s/  CONSTANCE RYAN      
	 	By:	 	/s/  EDWARD L. ERICKSON      

	Name:	 	Constance Ryan
	 	Name:	 	Edward L Erickson

	Title:	 	President
	 	Title:	 	Chairman, President and CEO

	Date:	 	7/30/02
	 	Date:	 	7/02/2002

-17-

 

APPENDIX A: Streck Technology 

	1.
	Streck
Patents

 

U.S.
Patent No. 5,459,073

 

U.S.
Patent No. 5,849,517

All
patents and patent applications in all countries of the world based upon, or claiming priority from, the above-referenced U.S. patents. 

	2.
	Cyto-Chex
Immunicon Formulation Sheet, Streck [**] and documents referenced therein.

	3.
	Immunicon
IC Sample Tube Formulation Sheet [**] and documents referenced therein.

	4.
	Purchase
specifications

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

-18-

QuickLinks

Exhibit 10.47

NON-EXCLUSIVE LICENSE AGREEMENT By and Between IMMUNICON CORPORATION and STRECK LABORATORIES, INC.QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.55    
    

        ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant
to a confidential treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

 
 

CellTracks(TM) AutoPrep(TM) SUPPLY AGREEMENT
  BETWEEN
  IMMUNICON CORPORATION
  AND
  ASTRO INSTRUMENTATION L.L.C.    
    

 

 
 

SUPPLY AGREEMENT    
    

        This Supply Agreement ("Agreement") is effective on the date of last signature ("Effective Date") by and between Immunicon Corporation, 3401 Masons Mill Road,
Suite 100, Huntingdon Valley, PA 19006 ("Immunicon") and Astro Instrumentation L.L.C., 22740 Lunn Road, Strongsville, Ohio 44149 ("Astro") 

        WHEREAS,
Immunicon desires that Astro manufacture and supply certain instrumentation to Immunicon having specifications supplied to Astro by Immunicon; and 

        WHEREAS, Astro desires to be the manufacturer and supplier of such instrumentation for Immunicon, and shall be sometimes referred to
herein as "SUPPLIER"; and 

        WHEREAS,
Astro and Immunicon now wish to set forth the terms and conditions of such manufacturing and supply arrangement between them. 

        Now,
therefore, in consideration of the above premises and the mutual covenants herein set forth, the parties hereto agree as follows: 

	1.
	Definitions

For
purposes of this Agreement: 

	1.1
	"Affiliate"
shall mean with respect to a party, an entity which, directly or indirectly, majority owns, or is majority owned by, or is under common majority ownership with, that
party. For the purposes hereof, a partnership shall be deemed an Affiliate if a party hereto is the managing partner or is a general partner and has an active and significant economic interest
therein.

	1.2
	"PRODUCTS"
shall mean the instrument system designated by Immunicon as the CellTracks(TM) AutoPrep(TM) system as listed in APPENDIX "C" to this Agreement, including parts,
subassemblies or components thereof, or any other product or products that the parties from time to time hereafter may mutually agree to add to this Agreement, which are supplied to Immunicon
hereunder. The specifications for these PRODUCTS and the processing and test instructions for each, are described in detail as specifications on drawing numbers provided to SUPPLIER and referenced in
APPENDIX "C".

	1.3
	"TEST
REPORT" shall mean the actual measurements recorded on a paper printout upon the completion of test procedures indicated on Immunicon specifications for the PRODUCTS tested
prior to shipment.

	1.4
	"Schedule"
shall mean a document issued by Immunicon, which specifies "releases" for delivery of PRODUCT(S).

	2.
	Term/Appointment of SUPPLIER/Exclusivity

	2.1
	The
initial term of this Agreement shall continue for two (2) years following the Effective Date unless terminated earlier pursuant to the express terms of this Agreement. This
Agreement shall automatically renew for successive one-year terms unless Immunicon gives SUPPLIER written notice of its intent not to renew at least ninety (90) days prior to the
end of the then-current term. Subject to fulfillment of its obligations under the terms and conditions of this Agreement, SUPPLIER shall produce and supply to Immunicon all of Immunicon's
requirements of the PRODUCTS defined herein during the initial term of this Agreement and any renewal thereof, unless this Agreement is terminated as permitted herein or the provisions of
section 2.2 become applicable. In addition to the other obligations of SUPPLIER hereunder, SUPPLIER shall provide on time delivery of quality PRODUCTS to Immunicon, time being of the essence
under this Agreement. 

2

 
	2.2
	In
the event SUPPLIER fails to supply Immunicon's requirements of PRODUCTS or fails to timely deliver quality PRODUCTS to Immunicon under section 2.1 at any time while this
Agreement is in effect, Immunicon shall, in addition to any other rights and remedies it may have arising from such failure and regardless of whether Immunicon exercises its right of termination
hereunder, have the right thereafter to obtain from any third party products substantially the same as or similar to PRODUCTS in order to meet its requirements thereof. In the event Immunicon obtains
such third party products under this section 2.2, SUPPLIER shall be relieved of its obligation hereunder to supply Immunicon's requirements of PRODUCTS.

	2.3
	SUPPLIER
shall manufacture and supply PRODUCTS exclusively to Immunicon, and Immunicon grants no license or other rights in or to PRODUCTS to SUPPLIER except to manufacture and supply
same to Immunicon. While this Agreement is in effect and for a period of [**] years after this Agreement is terminated for any reason, SUPPLIER not develop, manufacture or
sell, nor shall SUPPLIER directly or indirectly assist any third party to develop, manufacture or sell, any products which are competitive with the PRODUCTS supplied to Immunicon by SUPPLIER under
this Agreement, without the prior express written consent of Immunicon. For purposes of this Agreement, a product shall be considered competitive with the PRODUCTS supplied to Immunicon under this
Agreement if such product is useful in the cellular diagnostics, cellular separation or cellular enrichment fields.

	2.4
	The
parties acknowledge that Immunicon is not obligated to buy any specific amount of PRODUCTS under this Agreement, except as may otherwise be expressly set forth in this Agreement
or agreed in a separate writing between the parties.

	3.
	Agreement to Manufacture and Manufacturing Responsibilities

	3.1
	SUPPLIER
shall manufacture the PRODUCTS to the specifications and procedures provided to SUPPLIER by Immunicon. SUPPLIER also agrees to allow compliance with these specifications and
procedures to be audited by Immunicon's Quality Assurance/ Supplier Development Group or other representatives of Immunicon, at Immunicon's request. It is further understood that SUPPLIER shall have
primary responsibility for management of its suppliers and the resolution of technical issues. Failure of SUPPLIER to meet such specifications and procedures supplied by Immunicon shall be deemed a
material breach of this Agreement.

	3.2
	SUPPLIER
shall notify Immunicon in writing prior to the implementation of any process change or the use of any manufacturing facility which differ from those processes or facilities
being used to produce PRODUCTS at the Effective Date of this Agreement.

	3.3
	Engineering Changes.

	3.3.1
	Immunicon
may request to SUPPLIER in writing (via its Engineering Change Order or "ECO" document) that SUPPLIER incorporate engineering changes to any PRODUCT. An Immunicon ECO with
a Immunicon Quality Assurance representative's signature is the only recognized communication of change for production released PRODUCTS. If the incorporation of such changes is agreed between
Immunicon and SUPPLIER, the PRODUCT pricing in SCHEDULES "B" and "C" shall be amended accordingly by mutual agreement of Immunicon and SUPPLIER. SUPPLIER shall not unreasonably refuse to incorporate
Immunicon's engineering changes in a PRODUCT when requested by Immunicon. A product transfer plan mutually agreed by Immunicon and SUPPLIER shall describe how changes are to be controlled, the
responsible parties named and how validation of the change will be handled.

	3.3.2
	Payment
of reasonable material scrap or other costs incurred by SUPPLIER due to an Engineering Change Order are the responsibility of Immunicon and are payable net thirty
(30) days from the time of ECO implementation. 

3

 
	3.4
	Testing.    SUPPLIER shall test PRODUCTS in accordance with the test procedures and specification procedures supplied by
Immunicon and mutually agreed upon. Any test equipment supplied to SUPPLIER by Immunicon or designed and fabricated by SUPPLIER for testing PRODUCTS shall be maintained and calibrated by SUPPLIER at
its expense. SUPPLIER shall modify such test equipment as engineering changes to the PRODUCTS requested by Immunicon or mutually agreed upon process changes require. The reasonable costs of such
changes shall be at the expense of Immunicon.

	3.5
	Immunicon
shall have the right to add additional products to this Agreement upon acceptance by SUPPLIER, all of which added products shall become PRODUCTS as defined herein.

	3.6
	Tooling.    Immunicon will solely own all tooling funded by Immunicon to produce PRODUCTS, and during the term of this
Agreement SUPPLIER shall use tooling exclusively for the manufacture of PRODUCTS. The cost of all such tooling shall be mutually agreed between Immunicon and SUPPLIER before ordering. SUPPLIER shall
use and maintain all Immunicon owned tooling with the same level of care it would for its own tooling.. If major repair of tooling is due to causes other than SUPPLIER's neglect, misuse or other cause
attributable to SUPPLIER, Immunicon will be responsible for the costs thereof, provided Immunicon is fully informed in advance of the necessity of incurring such costs and agrees to such costs.

	3.7
	Material Purchases and Supply Chain Management.    SUPPLIER is responsible for planning, purchasing, quality assurance, and
payment for all materials needed to satisfy SUPPLIER'S obligations under this Agreement. SUPPLIER shall have sole responsibility to resolve all material, technical and quality issues related to
sub-tier suppliers; provided, however, that Immunicon may, at its discretion, assist SUPPLIER in such resolution. However, Immunicon will be responsible for the cost of parts and other
materials for manufacturing PRODUCTS that are purchased at risk by SUPPLIER to fulfill any order submitted by Immunicon under section 4.2 if such parts or materials are changed or other parts
or materials other than those specified for fulfilling the order are substituted in place of such parts or materials at the request of Immunicon, or the order is delayed or terminated by Immunicon.

	4.
	Commercial Terms and Pricing

	4.1
	Purchase
Orders. Immunicon shall place its orders for PRODUCTS and spare PRODUCTS on Immunicon Purchase Order forms which are substantially the same as the Purchase Order attached
hereto in APPENDIX "A". The provisions printed on the reverse side of such Purchase Orders shall be binding upon the parties and are incorporated herein by reference, and shall control except where
they are inconsistent or in conflict with the provisions of this Agreement, in which case the provisions of this Agreement shall govern and prevail.

	4.2
	Ordering and Forecasts.    Immunicon shall specify its expected requirements for PRODUCTS to be manufactured by SUPPLIER and
delivered to Immunicon under this Agreement by issuing a 12-month rolling forecast on a monthly basis. Immunicon will notify SUPPLIER of its delivery requirements using a "schedule"
document, which specifies "release" quantities with respect to the then monthly commitment quantity or some other quantity to be mutually agreed. The "schedule" document will reference the Purchase
Order. 

This
12-month rolling forecast is divided into the following three (3) periods: 

 Frozen period:  

Within
this rolling period the delivery dates and quantities are fixed. The length of this 

4

 

Period
will be four (4) weeks. Immunicon commits to receiving and not amending the specific weekly quantities within this rolling period, without prior agreement with SUPPLIER—only
weekly quantities outside this period can be subject to change. 

 Variable period:  

This
rolling period follows immediately after the frozen period. The length of this period will be for eight (8) weeks. During this variable period SUPPLIER is allowed to purchase parts and, if
necessary assemble PRODUCTS in order to meet the required delivery date of PRODUCTS. Immunicon is obliged to purchase these PRODUCTS without a delivery
date being determined. 

 Informative period:

This
period follows immediately after the variable period. The length of this period will be for the balance of the rolling twelve (12) month period. During this period Immunicon has no
obligation to purchase any PRODUCTS. Immunicon's liability with respect to "long lead items" and/or "end of life items", outside the first two periods above (totaling twelve weeks), will be honored in
accordance with section 10 of this Agreement. 

	4.3
	Pricing and Cost Reductions.    SUPPLIER shall sell to Immunicon PRODUCTS at a firm and fixed price per SCHEDULE "B" for one
(1) year following the execution of this Agreement. Thereafter, both parties agree to open book pricing during the remainder of the term of this Agreement, as defined in the structure shown in
SCHEDULE "B". Immunicon may require SUPPLIER to purchase materials from lower tier suppliers ("source controlled suppliers"). If the price of such lower
tier supplied material (third party to SUPPLIER) changes from time to time, the new price of material will be reflected in the pricing structure in  "SCHEDULE B" as mutually agreed by Immunicon and SUPPLIER and a new PRODUCT selling price will be placed
in effect at a time that the new cost is incurred by SUPPLIER.

	4.3.1
	Sharing of Cost Savings.    SUPPLIER may at any time, suggest to Immunicon changes, however small, that will result in
improved performance, reliability or yield of PRODUCTS. SUPPLIER agrees to perform value engineering and value analysis with the goal of reducing the costs of PRODUCTS over the commercial life of the
PRODUCTS. If Immunicon decides to purchase additional tooling to increase production of assemblies of an existing design, the cost reductions that occur as a result of this activity will be passed on
to Immunicon upon implementation of the tooling and use of the parts in production. If Immunicon recommends any changes to an existing design that reduce costs, these cost reductions or changes are to
be reflected in a lower unit price. Changes that are suggested by SUPPLIER and accepted by Immunicon, shall upon implementation, be shared equally between both parties.

	4.4
	Packaging.    SUPPLIER shall package all PRODUCTS in suitable containers for protection during shipments by air or ocean
freight worldwide and for storage. Packaging shall be mutually agreed between Immunicon and SUPPLIER. A PRODUCTS transfer plan will reference the qualification requirements for packaging.

	4.5
	SUPPLIER
will provide with each shipment of PRODUCTS a copy of the "TEST REPORT" for each individual PRODUCT contained therein.

	4.6
	Immunicon Purchasing Rights.    It is understood and agreed that purchases under this Agreement, and in furtherance thereof,
may be made directly from SUPPLIER by Immunicon's' parent, affiliate or subsidiary companies, or other sources authorized by Immunicon in writing to SUPPLIER, and the provisions contained herein shall
be equally applicable to said purchases. 

5

 
	4.7
	PAYMENT—SUPPLIER shall be paid pursuant to each invoice for PRODUCTS net 30 days following shipment of such PRODUCTS
from the factory (Strongsville, OH).

	5.
	Quality, Workmanship, and Warranty

	5.1
	SUPPLIER
agrees to comply with Immunicon's Quality Assurance Procedures and Immunicon engineering documentation for all PRODUCTS. A Device History Record (DHR) is to be maintained by
SUPPLIER for assemblies of PRODUCTS. For the purposes of this Agreement, it is understood and agreed that these procedures are the only recognized forms of communicating the provisions contained
therein between Immunicon and SUPPLIER. A PRODUCTS transfer plan will be followed that will describe the criteria for acceptance and successful transfer of PRODUCTS.

	5.2
	Immunicon
is entitled to reject any PRODUCT received by Immunicon, its affiliate or subsidiary companies, or other sources, which fails to conform to the agreed upon acceptance
criteria whether such criteria are preliminary or final. SUPPLIER agrees to use its best effort and resources to immediately repair or replace any non-conforming PRODUCT within
30 days of receipt of returned material, provided that the component replacement time does not prohibit such a time period. All cost of shipment to and from SUPPLIER resulting from properly
rejected PRODUCTS found to be non-conforming shall be borne by SUPPLIER.

	5.3
	Return of goods.    In the case that Immunicon returns PRODUCTS to SUPPLIER for any reason, it is understood that Immunicon
will decontaminate these PRODUCTS or in the case that Immunicon is not capable of decontaminating these PRODUCTS shall remove all fluids and disposables associated therewith and tag the PRODUCTS as
Bio-Hazardous. All returned PRODUCTS shall have a Returned Material Authorization (RMA) number. RMA numbers shall be requested by Immunicon from SUPPLIER'S Customer Service Representative
for each PRODUCT to be returned, thereafter, within ten days after receipt of such number by Immunicon such PRODUCT will be shipped to SUPPLIER. Additionally, SUPPLIER agrees to issue an RMA number to
Immunicon for return of PRODUCTS within (72) hours of Immunicon's request.

	5.4
	Warranty.    SUPPLIER warrants to Immunicon that PRODUCT manufactured and supplied to Immunicon shall conform to the
Immunicon specifications and/or any other mutually agreed upon acceptance criteria and shall be free from defects in workmanship and process related material defects for a period of (12) months
after shipping date. For Immunicon source controlled parts the warranty period will be no longer than given by the applicable vendor. SUPPLIER warrants to Immunicon that the PRODUCTS supplied to
Immunicon hereunder shall (a) comply in all material respects with the specifications for such PRODUCTS as supplied by Immunicon and Immunicon's acceptance criteria for such PRODUCTS and
(b) be manufactured in accordance with Immunicon's Quality Assurance Procedures and all applicable Federal, state and local laws, rules and regulations, including Good Laboratory Practices (as
defined in Federal Register 21 CFR Part 58) and Good Manufacturing Practices (as defined in Federal Register 21 CFR Part 110). 

Immunicon
shall perform initial warranty evaluation on the PRODUCTS and submit samples of returned PRODUCTS to SUPPLIER for its further evaluation and confirmation of defects of product failure. Upon
SUPPLIER confirmation, SUPPLIER shall replace, at its sole expense, the PRODUCT during the warranty period. Shipping charges to SUPPLIER for said defective PRODUCTS shall be paid by SUPPLIER, and
shall include but not be limited to, freight changes, time, and materials. Immunicon shall have no obligation to pay for any PRODUCT that does not comply with the specifications for such PRODUCT as
supplied by Immunicon to SUPPLIER or with Immunicon's acceptance criteria or with the warranties contained herein. SUPPLIER's liability with respect to any claim that a PRODUCT furnished hereunder to
Immunicon does not meet the foregoing shall be limited to the replacement of such PRODUCT at SUPPLIER's cost and expense, or a refund of the purchase price of such PRODUCT, SUPPLIER may elect. 

6

 

PRODUCTS
returned to SUPPLIER in which no defect due to SUPPLIER is found, shall be returned at the expense of Immunicon. SUPPLIER shall invoice Immunicon for costs incurred, to include but not be
limited to, freight changes, time, and materials. 

	5.6
	Immunicon,
at its option, shall have the right to source inspect any and all PRODUCTS at SUPPLIER's facility(s) prior to shipment by SUPPLIER to ensure conformity to Immunicon's
acceptance criteria, written specifications, test requirements, or other mutually agreed upon criteria.

	6.
	Spares Inventory    Immunicon shall provide a Recommended Spares List (RSL) for PRODUCTS and SUPPLIER shall maintain an
inventory of spares in accordance with the RSL sufficient while this Agreement is in effect to meet projected monthly requirements of such spares based on production lead times. Immunicon's
subsidiaries, affiliates, and other sources may order spares per the pricing listed in SCHEDULE C. SUPPLIER agrees to provide all of the spares
requirements for PRODUCTS for a period of no less than ten (10) years after delivery of the last PRODUCT to Immunicon hereunder. SUPPLIER shall be relieved of this obligation upon Immunicon's
execution of an agreement with another supplier for the supply of PRODUCTS substantially equivalent to the PRODUCTS supplied by SUPPLIER hereunder.

	7.
	Transfer of Title/Transportation    Title to all PRODUCTS shall transfer to Immunicon on shipment of the PRODUCT by SUPPLIER
to Immunicon. Immunicon shall pay the cost and insurance of transportation and shall instruct SUPPLIER as to the method of transportation to be used for each delivery. 

7

  

	8.
	Refurbishment

	

	SUPPLIER
further agrees to refurbish/repair out-of-warranty PRODUCTS or in-warranty PRODUCTS containing defects not caused by SUPPLIER,
based on Immunicon's instructions to Immunicon's original specifications, including all test requirements or other mutually agreed upon requirements. The cost to refurbish such PRODUCTS shall be
negotiated and agreed between SUPPLIER and Immunicon in good faith based on SUPPLIER "s normal overhead and profit rates and on the extent of labor and material required to restore the PRODUCTS to the
original Immunicon specifications. SUPPLIER shall provide Immunicon a written quotation for said refurbishment work within (15) business days of receiving returned PRODUCTS for evaluation.
Immunicon at its discretion shall indicate to SUPPLIER the shipping destination of such refurbished PRODUCTS.

	9.
	Force Majeure.

	9.1
	Failure
of either party to perform any of its obligations under this Agreement in whole or in part, shall be excused if such failure is the result of force majeure, including, but not
limited to, flood, wind and lightning, insurrections, strikes, riots, war and warlike operations, terrorism, civil commotion, fires, explosions, accidents, the acts or orders of any governmental
agency, acts of the public enemy, and laws or regulations or restrictions of the governmental entity or of any agency or instrumentality thereof.

	9.2
	If
performance of this Agreement is excused pursuant to the foregoing section the party thus excused shall use reasonable efforts to perform, and the party excused from performance
shall resume performance with the utmost dispatch when such circumstances are avoided, removed or corrected.

	9.3
	If
the circumstances of force majeure last longer than sixty (60) days, the party which has not declared the force majeure shall have the right to terminate this Agreement upon
thirty (30) days prior written notice to other party.

	10.
	Termination

	

	Immunicon
may terminate this Agreement, for any reason and without cause, on ninety (90) days written notice to SUPPLIER. In the event of termination under this
section, Immunicon shall pay SUPPLIER for non-cancelable costs actually incurred by SUPPLIER with respect to its manufacture and/or production of that quantity of PRODUCTS which is the
subject of a binding purchase order placed pursuant to section 4.1/4.2 above but not yet shipped. Long lead and end of life purchased parts that SUPPLIER placed on order to meet Immunicon's
forecast schedule shall be the liability of Immunicon.

	10.2
	In
the event that Immunicon wishes to terminate this Agreement, SUPPLIER, upon receipt of such written notice, shall stop work to the extent specified herein. Immunicon's termination
liability shall be limited to the following:

	a.
	Payment
for all PRODUCTS ordered and/or delivered to Immunicon and in -transit including finished PRODUCT in SUPPLIER's inventory prior to written notification of Termination.

	b.
	Payment
for all "Work -in-Process" based on the current SUPPLIER rate structure for labor and material mark-up.

	c.
	Payment
for all non-cancelable material purchase orders for Immunicon PRODUCTS plus material mark-up.

	10.3
	In
the event SUPPLIER wishes to terminate this Agreement, SUPPLIER may do so upon ninety (90) days prior written notice to Immunicon; provided, however that SUPPLIER shall
continue to 

2

 

supply
Production quantities of PRODUCTS to Immunicon to the extent that component parts and finished goods in SUPPLIER "s inventory may permit and give its best efforts to facilitate a smooth
transition of supply of PRODUCTS to Immunicon's designated source for further supply of PRODUCTS as may be requested by Immunicon, including transfer of all pertinent process "know how" and
documentation, tools and fixtures, and test equipment and any other material relevant to the manufacture of PRODUCTS. 

	10.4
	This
Agreement may be terminated at any time upon mutual written consent of the parties to this Agreement.

	10.5
	This
Agreement may be terminated by either party (a) immediately upon notice to the other party in the event that such other party is in material breach of this Agreement and
such breach remains uncured for a period of thirty (30) days following notice to the breaching party, or (b) immediately upon notice to the other party in the event that (i) such
other party shall (A) apply for or consent to the appointment of, or the taking of possession by, a receiver, custodian, trustee or liquidator of itself or of all or a substantial part of its
property, (B) make a general assignment for the benefit of its creditors, (C) commence a voluntary case under the United States Bankruptcy Code, as now or hereafter in effect (the
"Bankruptcy Code"), (D) file a petition seeking to take advantage of any law (the "Bankruptcy Laws") relating to bankruptcy, insolvency, reorganization, winding-up, or
composition or readjustment of debts, (E) fail to controvert in a timely and appropriate manner, or acquiesce in writing to, any petition filed against it in any involuntary case under the
Bankruptcy Code, or (F) take any corporate action for the purpose of effecting any of the foregoing; or (ii) a proceeding or case shall be commenced against such other party in any court
of competent jurisdiction, seeking (A) its liquidation, reorganization, dissolution or winding-up, or the composition or readjustment of its debts, (B) the appointment of a
trustee, receiver, custodian, liquidator or the like of the party or of all or any substantial part of its assets, or (C) similar relief under any Bankruptcy Laws, or (iii) an order,
judgment or decree approving any of the foregoing shall be entered and continue unstayed for a period of 60 days; or an (iv) order for relief against such other party shall be entered in
an involuntary case under the Bankruptcy Code. The termination or expiration of this Agreement shall neither release either party from the obligation to pay any sum that may be owing to the other, nor
operate to discharge any liability that had been incurred by either party prior to any such termination or expiration including, but not limited to, any obligation to deliver or pay for PRODUCTS or
complete purchase orders accepted hereunder. Neither party shall, by reason of the termination of this Agreement, be liable to the other for compensation, reimbursement or damages due to loss of
profits on sales or anticipated sales or losses due to expenditures, investments or commitments made in connection with this Agreement or the establishment, development or maintenance of the business
or goodwill of either party or on account of any cause whatsoever.

	11.
	Confidentiality/Patent Rights

	

	Immunicon
and SUPPLIER have both signed a Confidentiality Agreement under separate cover (APPENDIX "B") and same shall become part of this Agreement. The terms and
conditions of the signed Confidentiality Agreement shall govern exchanges of information between the parties hereto and shall survive this Agreement. The term of said signed Confidentiality Agreement,
if shorter than the term of this Agreement, shall be extended for the period of time that this Agreement is in effect. SUPPLIER acknowledges that PRODUCTS contain proprietary technology of Immunicon
and may be the subject of patents and patent applications that are owned by or licensed to Immunicon and/or its Affiliates. No right or license is granted to SUPPLIER with respect to any such
proprietary technology, patents or patent applications hereunder except the limited, nonexclusive, revocable right and license to utilize the foregoing for the manufacture and sale of PRODUCTS to
Immunicon under this Agreement. Upon termination of this Agreement, such license shall be null and void. The purchase by and transfer of title to Immunicon of 

3

 

PRODUCTS
hereunder, shall grant to Immunicon the non-revocable and fully-transferable right and license under any intellectual property or other proprietary rights of SUPPLIER embodied in
such PRODUCTS, to use and have used, sell and have sold, distribute and have distributed, and dispose of and have disposed of, such PRODUCTS and components of such PRODUCTS, without restriction of any
kind. 

	12.
	Right of Inspection

	12.1
	Immunicon
shall have the right under normal business hours to visit SUPPLIER's facilities to conduct evaluations and review the performance of SUPPLIER's obligations under this
Agreement. Immunicon shall also have the right to meet with SUPPLIER personnel and review development, production, process, and quality records relevant to the subject matter in this Agreement subject
to the confidentiality Agreement signed under separate form between SUPPLIER and Immunicon. Immunicon shall provide reasonable notice to SUPPLIER prior to each such visit.

	13.
	Complete Agreement

	13.1
	The
terms and conditions of this Agreement shall supercede and replace any previous terms and conditions of any agreement or understanding between SUPPLIER and Immunicon relating to
the supply of PRODUCTS to Immunicon by SUPPLIER, whether written or oral, except for the terms and conditions of the Confidentiality Agreement referenced in sections 11 and 12 to the extent not
inconsistent herewith.

	14.
	Governing Law

	14.1
	The
construction, validity and performance of this Agreement shall be governed by the laws of the state of Delaware, without giving regard to its
choice-of-law rules.

	15.
	Indemnification

	15.1
	Immunicon
agrees, at its cost, to indemnify, defend and hold SUPPLIER harmless from any claim by any person, firm, corporation or governmental unit which arises out of the sale or
use of the PRODUCTS supplied hereunder to Immunicon with respect to property damage/bodily injury only, except to the extent such claim is caused by or arises out of the intentional malfeasance or
negligent acts or omissions of SUPPLIER. SUPPLIER agrees, at its cost, to indemnify, defend and hold Immunicon harmless from any claim by any person, firm, corporation or governmental unit which
arises out of the manufacture or supply of the PRODUCTS hereunder or the breach of any of SUPPLIER's warranties under this Agreement, except to the extent such claim is caused by or arises out of the
intentional malfeasance or negligent acts or omissions of Immunicon, and in respect to such indemnification SUPPLIER shall maintain in force a general liability insurance policy having coverage
provisions applicable to any such claims and having a minimum limit of Five Million Dollars ($5,000,000) per occurrence, and naming Immunicon as an additional insured. SUPPLIER shall, promptly
following the Effective Date of this Agreement, provide a certificate of insurance to Immunicon as evidence of such insurance coverage.

	16.
	Assignment:    Neither party may directly or indirectly assign or transfer this Agreement, in whole or on part, to any third
party without the other party's prior written consent, which consent shall not be unreasonably withheld or delayed. Notwithstanding the above, either Immunicon or SUPPLIER may assign its rights and
obligations hereunder to a subsidiary or Affiliate or to a purchaser of its business relating to the PRODUCTS without the prior written consent of the other. This Agreement shall be binding upon and
inure to the benefit of the parties hereto and their respective successors and permitted assigns.

	17.
	Severability:    In the event of any provision of this Agreement shall be deemed to be invalid, void, illegal, or
unenforceable, the remaining provisions hereof nevertheless will continue in full force and effect without being impaired or invalidated in any way. 

4

 
	18.
	Notices

	18.1
	Any
notices from either party which affect this Agreement shall be in writing and sent by certified mail, fax or courier to the address of that party as set out below or such other
address as may from time to time have been notified in writing by either company in question to the other. 

	 	 	In the case of notices to Immunicon Corporation:
	

 	
 	

Immunicon Corporation

3401 Masons Mill Road, Suite 100

Huntingdon Valley, PA 19006-3574

For the attention of: Vice President of Engineering
	

 	
 	

With a copy to
	

 	
 	

Immunicon Corporation

3401 Masons Mill Road, Suite 100

Huntingdon Valley, PA 19006-3574

For the attention of: Chief Financial Officer
	

 	
 	

In the case of notices to SUPPLIER:

Astro Instrumentation L.L.C.

22740 Lunn Road

Strongsville, Ohio 44149

For the attention of:

Vice President / General Manager

	19.
	Privity:    The relationship established between SUPPLIER and Immunicon shall be solely that of seller and buyer, and neither
party shall be in any way the agent or representative of the other party for any purpose whatsoever, and shall have no right to create or assume any obligation or responsibility of any kind, whether
express or implied, in the name of or on behalf of the of the party to bind the other party in any manner whatsoever. The status of the parties is as independent contractors, and this Agreement does
not create any partnership, association, or other business entity, nor shall anything herein be deemed to constitute either party an agent of the other, and neither party shall make any statements or
representations to the contrary by advertising, signs, letterheads, or otherwise. No contracts, commitments, statements, or representations made by or on behalf of either party shall be binding in any
respect on the other party. Unless specifically provided elsewhere herein, nothing in this Agreement is intended to benefit any person or entity not a party hereto. This Agreement shall be binding
upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns

	20.
	Validity of Agreement Signed in Counterpart

This
Agreement may be signed in counterparts, each of which shall be an original, but all of which shall be deemed to be one and the same instrument, and shall be valid and binding when so signed. 

	21.
	The
article, section and paragraph headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this
Agreement.

	22.
	The
failure of either party to enforce at any time for any period any provision hereof shall not be construed to be a waiver of such provision or of the right of such party thereafter
to enforce each such provision, nor shall any single or partial exercise of any right or remedy hereunder preclude any other or further exercise thereof or the exercise of any other right or remedy.
Remedies provided herein are cumulative and not exclusive of any remedies provided at law. 

5

 
	23.
	Any
controversy or claim arising out of or relating to this Agreement shall be resolved by arbitration before a single arbitrator in accordance with the Commercial Arbitration Rules
of the American Arbitration Association ("AAA") then pertaining (available at www.adr.org), except where those rules conflict with this provision, in which case this provision controls. Any court with
jurisdiction shall enforce this clause and enter judgment on any award. The arbitrator shall be selected within twenty business days from commencement of the arbitration from the AAA's National Roster
of Arbitrators pursuant to agreement or through selection procedures administered by the AAA. Within 45 days of initiation of arbitration, the parties shall reach agreement upon and thereafter
follow procedures, including limits on discovery, assuring that the arbitration will be concluded and the award rendered within no more than eight months from selection of the arbitrator or, failing
agreement, procedures meeting such time limits will be designed by the AAA and adhered to by the parties. The arbitration shall be held in Philadelphia, Pennsylvania and the arbitrator shall apply the
substantive law of Delaware, except that the interpretation and enforcement of this arbitration provision shall be governed by the Federal Arbitration Act. Prior to commencement of arbitration,
emergency relief is available from any court to avoid irreparable harm. THE ARBITRATOR SHALL NOT AWARD EITHER PARTY PUNITIVE, EXEMPLARY, MULTIPLIED OR CONSEQUENTIAL DAMAGES, OR ATTORNEYS FEES OR
COSTS. Prior to commencement of arbitration, the parties must attempt to mediate their dispute using a professional mediator from AAA, the CPR Institute for Dispute Resolution, or like organization
selected by agreement or, absent agreement, through selection procedures administered by the AAA. Within a period of 45 days after the request for mediation, the parties agree to convene with
the mediator, with business representatives present, for at least one session to attempt to resolve the matter. In no event will mediation delay commencement of the arbitration for more than
45 days absent agreement of the parties or interfere with the availability of emergency relief. 

6

 

        IN
WITNESS WHEREOF, the parties have caused their respective duly authorized representatives to sign this Agreement in counterparts, putting this Agreement in effect as of the date of
both parties' signatures. 

	ASTRO INSTRUMENTATION, LLC	 	 	IMMUNICON CORPORATION
	

/s/  DUANE STIERHOFF      
 Signed by:

Duane Stierhoff

Vice President / General Manager

Astro Instrumentation	
 	

 	

/s/  KATHARINE W. HAWES      
 Signed by:

VP of Operations
	

11/24/03
 Dated:	
 	

 	

12/13/03
 Dated:

7

  

 
 

SCHEDULE "A"    
    

Blank Page

  Schedule "A" Removed from Text of Agreement 

8

  

 
 

SCHEDULE "B"    
    

PRODUCTION PRICING  

Material Cost is equal to the total cost of the parts to produce the Product. 

Material
Mark-Up—[**] 

	Labor Rate—	Assembly Rate is [**]

Test Rate is [**].

Selling
Price Formula

[**] 

	PART NUMBER
	 	DESCRIPTION
	 	QUANTITY
	 	UNIT PRICE

	[**]	 	[**]	 	[**]	 	[**]
	[**]	 	[**]	 	[**]	 	[**]
	[**]	 	[**]	 	[**]	 	[**]

        **    Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a
confidential treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

9

  

 
 

SCHEDULE "C"    
    

 
  SPARES PRICING    
    

	PART NUMBER
	 	DESCRIPTION
	 	QUANTITY
	 	UNIT PRICE

	TBD	 	TBD	 	TBD	 	TBD

See Attached Sheets  

	[**]
	[Information from 3 attached sheets has been omitted and will be filed separately with the Securities and Exchange
Commission pursuant to a confidential treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.]

 
	**
	 Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment
request under
17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.  

10

   APPENDIX "A"

IMMUNICON PURCHASE ORDER

STANDARD TERMS AND CONDITIONS  

COPY OF IMMUNICON PURCHASE ORDER TO BE ATTACHED  

A-1

 

	[IMMUNICON LOGO]	 	Purchase Order
	 	 	

	 	 	NUMBER	 	DATE	 	PAGE
	 	 	

	 	 	 	 	11/17/03	 	1
	 	 	

	3401 MASONS MILL ROAD, SUITE 100

HUNTINGDON VALLEY, PA 19006-3574

PHONE: 215-830-0777        FAX: 215-830-0751	 	 	 	 	 	 
		 	 	 	 	 	 

	VENDOR:	 	 	 	DELIVER TO:	 	 
	 	 	Astro Instrumentation LLC

22740 Lunn Road

Strongsville, OH 44149	 	 	 	IMMUNICON CORPORATION

3401 MASONS MILL ROAD

SUITE 100

HUNTINGDON VALLEY, PA 19006
	
	 	 	 	 	 	 

	SUPPLIER	 	CONTACT/PHONE	 	PHONE/FAX	 	SHIP VIA
	ASTR001	 	 	 	 	 	 
	
	 	 	 	 	 	 

	BUYER	 	PAYMENT TERM	 	F.O.B
	JH	 	Net 30	 	ORIGIN
		 	 	 	 

	CATALOG NO.	 	ORDER

QTY	 	ITEM

Division	 	DESCRIPTION	 	DUE

DATE	 	UNIT

PRICE	 	NET AMT
	

 	
 	

 	
 	

 	
 	

 	
 	

 	
 	

 	
 	

 
	

	
 	

 	
 	

 	
 	

 	
 	

 	
 	

 	
 	

 

	 	 	 	 	

	o Certificate of Analysis Required	 	o Certificate of Compliance Required	 	TOTAL	 	0.00
	 	 	 	 	

	Suppliers are required to notify Immunicon of any changes to this product in advance for approval by Immunicon. Immunicon reserves the right to conduct a supplier's assessment of any supplier. These
assessments do not relieve the supplier from providing acceptable product as verified through receiving inspections	 	PURCHASING APPROVAL	 	DATE
	 	 	 	 	

A-2

  

 
 

APPENDIX "B"    
    

 
  IMMUNICON / ASTRO CONFIDENTIALITY AGREEMENT    
    

B-1

 

 
 

CONFIDENTIALITY AGREEMENT    
    

 
 

Effective Date:
  August 20, 2001    
    

        In order to protect certain confidential information, relating to research, development, business plans, and other technology including materials ("Information"),
which may be disclosed between them, Immunicon Corporation ("IMMUNICON") and the "Participant" identified below, intending to be legally bound, agree that: 

1.    The
Discloser(s) of information is (are): 

IMMUNICON CORPORATION and ASTRO INSTRUMENTATION ("Participant")

2.    A
party ("Disclosing Party") may disclose information to the other ("Receiving Party"). The parties disclosing or receiving information: 

	a)
	IMMUNICON CORPORATION

Huntingdon Valley, PA 19006

 
	b)
	 ASTRO INSTRUMENTATION L.L.C.

Strongville, OH 44149  

3)    Information disclosed under this Agreement is described as: 

Immunicon:

Technical
information relating to sample preparation methods and high gradient magnetic separation technologies and their usage in diagnostic applications. 

Astro
Instruments: 

Technical
information relating to diagnostic instrumentation designs including but not limited to biological sample handling, sensing and control. 

4.    This
agreement controls only information which is disclosed to the Receiving Party from the Effective Date to August 20, 2003, and the Receiving Party's duties under
Paragraphs 5 through 8 of this Agreement expire five (5) years after each such disclosure. 

5.    The
Receiving Party shall use the information of the Disclosing Party solely for purposes of discussion and evaluation. The Receiving Party will not disclose the information of the
Disclosing Party to any person except its employees, consultants, or subcontractors to whom it is necessary to disclose the
information for such evaluation and any such disclosure shall be under terms at least as restrictive as those specified herein. Any of the persons mentioned above who are given access to the
information shall be informed of this Agreement. The Receiving Party shall protect the information by using the same degree of care, but not less than a reasonable degree of care, as the Receiving
Party uses to protect its own confidential information. 

6.    The
Receiving Party's duties under this Agreement shall apply only to information in any written document, memorandum, report, correspondence, drawing or other material, or computer
software or program, developed or prepared by the Disclosing Party or any of its representatives which have been clearly marked "Confidential" within thirty (30) days after disclosure to be
considered confidential information. Disclosures in the form of tangible products or materials must be transmitted to the Receiving Party with an accompanying written memorandum to be considered
confidential information. 

7.    Notwithstanding
any other provision of this Agreement, information shall not include any item or information, data, patent or idea which: (a) is within the public domain prior
to the time of disclosure by the Disclosing Party to the Receiving Party or thereafter becomes within the public domain other 

B-2

 

than
as a result of disclosure by the Receiving Party or any of its representatives in violation of this Agreement; (b) was, on or before the date of disclosure in the possession of the
Receiving Party; (c) is acquired by the Receiving Party from a third party not under an obligation of confidentiality; or (d) is hereafter independently developed by the Receiving Party,
without reference to the information received from the disclosing Party. 

8.    The
receiving Party agrees to return all information, including materials, received from the Disclosing Party at the request of the Disclosing Party except that the Receiving Party may
retain in its confidential files one copy of written information for record purposes only. 

9.    In
the event that the Receiving Party or anyone to whom it transmits the information pursuant to this Agreement becomes legally required to disclosed any such information, the
Receiving Party shall provide the Disclosing Party with prompt notice so the Disclosing Party may seek a protective order or other appropriate remedy and/or waive compliance with the provisions of
this Agreement. In the event that such protective order or other remedy is not obtained, the Receiving Party shall furnish only that portion of this Proprietary Information that is legally required. 

10.    This
agreement is made under and shall be construed in accordance with the laws of the Commonwealth of Pennsylvania and constitutes the entire understanding between the Parties hereto
with respect to the subject matter hereof and merges any and all prior agreements, understandings and representations. This agreement may not be superseded, amended or modified except by written
agreement between the parties hereto. 

11.    The
Parties hereto have caused this Agreement to be executed on its behalf in duplicate (each of which duplicates shall be deemed to be an original) to be effective on the Effective
Date. 

	IMMUNICON CORPORATION

Huntingdon Valley, PA 19006	 	ASTRO INSTRUMENTATION

Strongsville, OH 44149
	

/s/  MICHAEL KAGAN      
 Michael Kagan

Vice President, Engineering	
 	

/s/  TONY BLAIR      
 Tony Blair

Director of Business Development
	

Date:	

8-13-01	
 	

Date:	

8-10-01
	 	
	 	 	

B-3

  

 
 

APPENDIX "C"
  Instrument System List    
    

	PART NUMBER
 
	 	DESCRIPTION
 

	0040-0065	 	Autoprep System
	

0040-0066	
 	

Waste Water Module
	

0040-0062	
 	

Installation Kit

C-1

QuickLinks

Exhibit 10.55

CellTracks(TM)  AutoPrep(TM) SUPPLY AGREEMENT BETWEEN IMMUNICON CORPORATION AND ASTRO INSTRUMENTATION L.L.C.

SUPPLY AGREEMENT

SCHEDULE "A"

SCHEDULE "B"

SCHEDULE "C"

SPARES PRICING

APPENDIX "B"

IMMUNICON / ASTRO CONFIDENTIALITY AGREEMENT

CONFIDENTIALITY AGREEMENT

Effective Date: August 20, 2001

APPENDIX "C" Instrument System List

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00063-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00063-of-00352.parquet"}]]